Search Results

Infinity Pharmaceuticals, Inc. announced today that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that Infinity stockholders vote FOR the merger with MEI Pharma, Inc.

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”) at the special meeting of Infinity stockholders held earlier today (the “Special Meeting”).

Infinity Pharmaceuticals, Inc. announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”).

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

Infinity Pharmaceuticals, Inc. announced a series of actions designed to reduce the Company’s burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc.

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

Infinant Health announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology.